A5047338851- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
- Rheumatoid Arthritis Research and Therapies
- Vaccine Coverage and Hesitancy
- Childhood Cancer Survivors' Quality of Life
- Intramuscular injections and effects
- Respiratory viral infections research
- Systemic Lupus Erythematosus Research
- SARS-CoV-2 and COVID-19 Research
Systemic juvenile idiopathic arthritis (sJIA) is of one or more joints accompanied preceded by confirmed intermittent fever at least 3 days duration for 2 weeks in combination with the following features: transient (volatile) erythematous rash, generalized lymphadenopathy, hepatomegaly and/or splenomegaly, serositis. Prior to invention genetically engineered biological drugs (GEBDs), therapeutic options patients JIA were limited use nonsteroidal anti-inflammatory (NSAIDs),...
Juvenile idiopathic arthritis (JIA) is the most frequent rheumatic disease of childhood. The goal juvenile therapy to achieve durable clinical and laboratory remission a good quality life. Various groups drugs are used in treatment JIA, one which anti-CD20 drug rituximab. Rituximab causes B-cell depletion, may lead decreased immunoglobulin levels, antigen-presenting function B-lymphocytes impaired T-cell response. main side effects rituximab administration infusion reactions,...
Vaccination of patients with immune-mediated diseases, such as inflammatory bowel diseases (IBD) and juvenile idiopathic arthritis (JIA), is an actual problem since these have increased risk developing infectious complications due to immunosuppressive therapy features the disease itself. The specialists’ attitude towards vaccination autoimmune has changed dramatically over past decades: from complete refusal previously almost implementation vaccine complex use vaccines outside national...
New coronavirus infection (COVID-19) is an acute respiratory disease caused by the SARS-CoV-2 coronavirus. Tixagevimab+cilgavimab has been developed for prevention and treatment of COVID-19. The purpose this research was to evaluate safety use two-component drug monoclonal antibodies (tixagevimab+cilgavimab) pre-exposure prophylaxis new in children with rheumatic diseases (RDs). Materials methods used: a single-center retrospective study prospective stage had carried out that included 300...
Severe acute respiratory syndrome virus SARS-CoV-2 is associated with the phenomenon of immune system dysregulation, which may serve as a trigger for development autoimmune diseases and secondary hemophagocytic (vHPS). Objective. To determine peculiarities clinical laboratory manifestations sHPS in children rheumatic (RD) developed after NCI (COVID-19). Patients methods. The study included 116 pediatric patients RH who underwent examination treatment at rheumatology department National...
Background. A register is a critical component of the healthcare system. It consists informational part (number patients, spectrum and severity pathology, dynamics each patient's condition, administration specific drugs, therapeutic effects) an analytical (treatment efficacy, planning individual regional needs for drugs effects, development evaluation management protocols, etc.). In Russia, despite existence National Federal Register, number parameters collected limited; Register lacks...
Systemic juvenile idiopathic arthritis (syn.: with systemic onset; hereinafter referred to as sJIA) is one of the most severe variants arthritis, in which at beginning disease it often not joint damage that comes fore, but manifestations such fever, rash, hepatosplenomegaly, lymphadenopathy and serositis. Tumor necrosis factor-α (TNF-α) inhibitors, successfully used therapy JIA without manifestations, are effective patients JIA. Thus, according BIKER registry (Germany), remission was...